Quick Answer
ADC Therapeutics SA reported Revenue (ASC 606) of $69.06 million for fiscal year 2023.
ADC Therapeutics SA Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $69.06M | -7.8% |
| 2022 | $74.91M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.75M | -12.6% | -12.9% |
| June 30, 2025 | $18.09M | +6.2% | +3.9% |
| March 31, 2025 | $17.40M | -2.5% | -3.4% |
| September 30, 2024 | $18.02M | +26.3% | +5.8% |
| June 30, 2024 | $17.03M | -11.3% | -4.6% |
| March 31, 2024 | $17.85M | -5.8% | +25.1% |
| September 30, 2023 | $14.27M | — | -25.7% |
| June 30, 2023 | $19.20M | — | +1.3% |
- ADC Therapeutics SA showed a decrease of -7.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2023 period, ADC Therapeutics SA’s revenue (asc 606) has declined by 7.8% (from $74.91 million to $69.06 million).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 13, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: